Business Context and Reporting Period
This Form 6-K filing covers the month of September 2019 for Midatech Pharma PLC (note: the request metadata lists "Biodexa Pharmaceuticals Plc," but the filing text identifies the registrant as Midatech Pharma PLC). The report details significant changes to the Company's executive leadership.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Resignation: Nicholas Robbins-Cherry resigned as a director and Chief Financial Officer effective September 9, 2019. The resignation was voluntary to pursue another opportunity and was not the result of any disagreements with the Company.
- Appointment: Stephen Stamp was appointed as the new Chief Financial Officer and a director of the Company on September 9, 2019.
- Transition: Mr. Robbins-Cherry remained employed by the Company until the end of October 2019 to facilitate an orderly handover.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It confirms there are no arrangements or understandings between Mr. Stamp and any other person regarding his appointment. The filing includes a Service Agreement as Exhibit 10.1, with certain portions omitted due to potential competitive harm.
Key Facts for Investor Verification
- Verify the correct registrant name is Midatech Pharma PLC, not Biodexa Pharmaceuticals Plc.
- Confirm the effective date of the CFO transition (September 9, 2019) and the end of the transition period (end of October 2019).
- Review the attached Service Agreement (Exhibit 10.1) for specific terms of Mr. Stamp's employment, noting that some details were redacted.